Related content

Comparing rosiglitazone with ethinylestradiol/cyproterone acetate in the treatment of polycystic ovary syndrome

By Pesant Marie-Hélène   Baillargeon Jean-Patrice  

Expert Review of Obstretrics and Gynecology, Vol. 1, Iss. 1, 2006-09 ,pp. : 81-92

Informa Healthcare

Access to resources Recommend Favorite

Efficacy of combined ethinyloestradiol (0.035 mg) and cyproterone acetate (2 mg) in acne and hirsutism in women with polycystic ovary syndrome

By Falsetti L.   Ramazzotto Francesca   Rosina Barbara  

Journal of Obstetrics & Gynaecology, Vol. 17, Iss. 6, 1997-12 ,pp. : 565-568

Informa Healthcare

Access to resources Recommend Favorite

Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes

By Villaseca P   Hormaza P   Cárdenas I   Oestreicher E   Arteaga E  

The European Journal of Contraception and Reproductive Health Care, Vol. 9, Iss. 3, 2004-09 ,pp. : 155-165

Informa Healthcare

Access to resources Recommend Favorite

Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome

By Winters S.J.   Talbott E.   Guzick D.S.   Zborowski J.   McHugh K.P.  

Fertility and Sterility, Vol. 73, Iss. 4, 2000-04 ,pp. : 724-729

Elsevier

Access to resources Recommend Favorite

Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome

By Azziz R.   Ehrmann D.A.   Legro R.S.   Fereshetian A.G.   O'Keefe M.   Ghazzi M.N.   PCOS/Troglitazone Study Group  

Fertility and Sterility, Vol. 79, Iss. 4, 2003-04 ,pp. : 932-937

Elsevier

Access to resources Recommend Favorite